Diplomat Pharmacy (NYSE:DPLO) and 111 (NASDAQ:YI) are both small-cap retail/wholesale companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.
This table compares Diplomat Pharmacy and 111’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations for Diplomat Pharmacy and 111, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Diplomat Pharmacy presently has a consensus price target of $24.50, indicating a potential upside of 58.78%. Given Diplomat Pharmacy’s higher possible upside, analysts clearly believe Diplomat Pharmacy is more favorable than 111.
Earnings and Valuation
This table compares Diplomat Pharmacy and 111’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Diplomat Pharmacy||$4.49 billion||0.26||$15.51 million||$0.84||18.37|
Diplomat Pharmacy has higher revenue and earnings than 111.
Institutional and Insider Ownership
83.5% of Diplomat Pharmacy shares are held by institutional investors. 24.7% of Diplomat Pharmacy shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Diplomat Pharmacy beats 111 on 8 of the 10 factors compared between the two stocks.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company's primary focus is on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. The company was founded in 1975 and is headquartered in Flint, Michigan.
111, Inc., through its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. It also offers a suite of cloud-based solutions and Internet-based software services, including the provision of access to business applications and service modules, such as customer relationship management, supply chain management, online medical consultation, e-prescriptions, digital contract sales organization, and precision marketing. In addition, the company is involved in warehousing, logistics, procurement, research and development, and consulting activities; and software development and information technology support businesses. As of June 30, 2018, 111, Inc. had a network of 12 offline retail pharmacies branded as Yi Hao Pharmacy in Guangzhou, Shanghai, Tianjin, and Kunshan. It services pharmacies, pharmaceutical companies, medical professionals and consumers. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2012 and is headquartered in Shanghai, China.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.